Gary R. Potter Knihy

Illegal drug use is prevalent globally, accompanied by evolving drug markets that respond to demand. Drug policies aim to address these issues, whether by eliminating use and supply or minimizing associated harms. The drug problem manifests differently across regions, with varying drug use prevalence and distinct drug cultures influenced by geographical, social, and cultural contexts. While global drug treaties provide a framework, local and national politics shape drug policies to address specific concerns. Understanding drug issues requires considering these geographical, cultural, and temporal dimensions. This work compiles contributions from various European experts, each examining different facets of the drug problem in diverse contexts. Each chapter offers valuable insights into specific aspects and examples, enhancing our understanding of the interplay between drug use, markets, and policy. Together, they illuminate how these elements are situated within their unique place, space, and time. The contributors include Gary R. Potter, Senior Lecturer in Criminology at Lancaster University Law School; Jane Fountain, research consultant and Emeritus Professor at the University of Central Lancashire; and Dirk Korf, Professor at the University of Amsterdam.

Patterns of drug use are changing, as are societal responses to the drug ‘problem’. In itself, this is not particularly noteworthy. However, in many ways we are experiencing change that is unprecedented in the history of drug policy. Many new developments are occurring simultaneously: technological advances enable new ways of producing and distributing both old and new drugs, and facilitate the dissemination of information that influences drug-taking behaviours. Those who seek to respond (including policy makers, treatment professionals, researchers) also harness scientific advances. The rate of change is such that it is difficult to keep up, or to predict the consequences. This book examines change and continuity in European drug scenes. Eight original research papers explore their own specific topics, features on the broader drug landscape. But individually and (especially) together, these studies provide broader insights relevant to many other aspects of the contemporary drug scene in Europe and beyond.